Does the Simultaneous Introduction of Several Pharmaceuticals in the Post-Lenalidomide Era Translate to Better Outcomes in Relapse Refractory Multiple Myeloma? Findings from the Real-World Innovation in Multiple Myeloma (REAL IMM) Study
Newer methodologies are needed to assess the real-world comparative effectiveness of a “generation” of pharmaceutical innovation versus the prior standard of care. This chart review study aimed to first evaluate the cumulative clinical benefits of pharmaceutical innovation in everyday relapse/refrac...
Saved in:
| Published in | Cancers Vol. 15; no. 24; p. 5846 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
MDPI AG
01.12.2023
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 2072-6694 2072-6694 |
| DOI | 10.3390/cancers15245846 |
Cover
| Abstract | Newer methodologies are needed to assess the real-world comparative effectiveness of a “generation” of pharmaceutical innovation versus the prior standard of care. This chart review study aimed to first evaluate the cumulative clinical benefits of pharmaceutical innovation in everyday relapse/refractory multiple myeloma before analyzing findings in the context of respective real-world outcomes from the bortezomib/lenalidomide era. Study endpoints included the 52-week PFS rate in second and third line of therapy (LOT), mPFS-2 across the first and second LOT, the ORR, reasons for discontinuation, and the treatment duration per therapeutic algorithm. Data from 107 patients were collected. The median follow-up was 2.0 years. Of the subjects who met the selection criteria for the second LOT, 72.2% maintained the PFS at 52 weeks. In the third-line setting, the PFS rate at 52 weeks was 63.5%. The mPFS across the first and second, the second, and the third LOTs were 26, 17, and 15 months, respectively. The ORR was 76.1% in the second and 69.7% in the third LOT. After non-response or progression, the main reason for drug discontinuation was treatment intolerability. The second-line ORR and the 52-week PFS rate were similar to previous real-world findings from the bortezomib/lenalidomide era. The cumulative mPFS across the second and third LOTs was higher than the respective mPFS across the first and second LOTs. Despite its limitations, the methodology and findings from this study may be used in future clinical and economic evaluations across all hematological malignancies. |
|---|---|
| AbstractList | Newer methodologies are needed to assess the real-world comparative effectiveness of a “generation” of pharmaceutical innovation versus the prior standard of care. This chart review study aimed to first evaluate the cumulative clinical benefits of pharmaceutical innovation in everyday relapse/refractory multiple myeloma before analyzing findings in the context of respective real-world outcomes from the bortezomib/lenalidomide era. Study endpoints included the 52-week PFS rate in second and third line of therapy (LOT), mPFS-2 across the first and second LOT, the ORR, reasons for discontinuation, and the treatment duration per therapeutic algorithm. Data from 107 patients were collected. The median follow-up was 2.0 years. Of the subjects who met the selection criteria for the second LOT, 72.2% maintained the PFS at 52 weeks. In the third-line setting, the PFS rate at 52 weeks was 63.5%. The mPFS across the first and second, the second, and the third LOTs were 26, 17, and 15 months, respectively. The ORR was 76.1% in the second and 69.7% in the third LOT. After non-response or progression, the main reason for drug discontinuation was treatment intolerability. The second-line ORR and the 52-week PFS rate were similar to previous real-world findings from the bortezomib/lenalidomide era. The cumulative mPFS across the second and third LOTs was higher than the respective mPFS across the first and second LOTs. Despite its limitations, the methodology and findings from this study may be used in future clinical and economic evaluations across all hematological malignancies. Simple SummaryOn rare occasions, a handful of innovative cancer drugs may successfully go through clinical trials and manage to obtain simultaneous regulatory approvals to treat a specific disease, providing hope for improved treatment outcomes. In the past few years, physicians in North America, Europe, and other countries with stronger economies have been able to use several of the recently approved drugs to treat a blood cancer called multiple myeloma, once older therapies have failed. This study looked at the treatment outcomes associated with the wave of newer drugs in patients diagnosed with multiple myeloma in Greece. The results showed that approximately three-quarters of patients who received one of the newer drugs after having progressed on front-line therapies remained in remission a year after initiating treatment. This finding was comparable to the results from previous studies in Greek patients who were diagnosed with relapsed or refractory multiple myeloma and had previously used other therapies.AbstractNewer methodologies are needed to assess the real-world comparative effectiveness of a “generation” of pharmaceutical innovation versus the prior standard of care. This chart review study aimed to first evaluate the cumulative clinical benefits of pharmaceutical innovation in everyday relapse/refractory multiple myeloma before analyzing findings in the context of respective real-world outcomes from the bortezomib/lenalidomide era. Study endpoints included the 52-week PFS rate in second and third line of therapy (LOT), mPFS-2 across the first and second LOT, the ORR, reasons for discontinuation, and the treatment duration per therapeutic algorithm. Data from 107 patients were collected. The median follow-up was 2.0 years. Of the subjects who met the selection criteria for the second LOT, 72.2% maintained the PFS at 52 weeks. In the third-line setting, the PFS rate at 52 weeks was 63.5%. The mPFS across the first and second, the second, and the third LOTs were 26, 17, and 15 months, respectively. The ORR was 76.1% in the second and 69.7% in the third LOT. After non-response or progression, the main reason for drug discontinuation was treatment intolerability. The second-line ORR and the 52-week PFS rate were similar to previous real-world findings from the bortezomib/lenalidomide era. The cumulative mPFS across the second and third LOTs was higher than the respective mPFS across the first and second LOTs. Despite its limitations, the methodology and findings from this study may be used in future clinical and economic evaluations across all hematological malignancies. On rare occasions, a handful of innovative cancer drugs may successfully go through clinical trials and manage to obtain simultaneous regulatory approvals to treat a specific disease, providing hope for improved treatment outcomes. In the past few years, physicians in North America, Europe, and other countries with stronger economies have been able to use several of the recently approved drugs to treat a blood cancer called multiple myeloma, once older therapies have failed. This study looked at the treatment outcomes associated with the wave of newer drugs in patients diagnosed with multiple myeloma in Greece. The results showed that approximately three-quarters of patients who received one of the newer drugs after having progressed on front-line therapies remained in remission a year after initiating treatment. This finding was comparable to the results from previous studies in Greek patients who were diagnosed with relapsed or refractory multiple myeloma and had previously used other therapies. Newer methodologies are needed to assess the real-world comparative effectiveness of a “generation” of pharmaceutical innovation versus the prior standard of care. This chart review study aimed to first evaluate the cumulative clinical benefits of pharmaceutical innovation in everyday relapse/refractory multiple myeloma before analyzing findings in the context of respective real-world outcomes from the bortezomib/lenalidomide era. Study endpoints included the 52-week PFS rate in second and third line of therapy (LOT), mPFS-2 across the first and second LOT, the ORR, reasons for discontinuation, and the treatment duration per therapeutic algorithm. Data from 107 patients were collected. The median follow-up was 2.0 years. Of the subjects who met the selection criteria for the second LOT, 72.2% maintained the PFS at 52 weeks. In the third-line setting, the PFS rate at 52 weeks was 63.5%. The mPFS across the first and second, the second, and the third LOTs were 26, 17, and 15 months, respectively. The ORR was 76.1% in the second and 69.7% in the third LOT. After non-response or progression, the main reason for drug discontinuation was treatment intolerability. The second-line ORR and the 52-week PFS rate were similar to previous real-world findings from the bortezomib/lenalidomide era. The cumulative mPFS across the second and third LOTs was higher than the respective mPFS across the first and second LOTs. Despite its limitations, the methodology and findings from this study may be used in future clinical and economic evaluations across all hematological malignancies. Newer methodologies are needed to assess the real-world comparative effectiveness of a "generation" of pharmaceutical innovation versus the prior standard of care. This chart review study aimed to first evaluate the cumulative clinical benefits of pharmaceutical innovation in everyday relapse/refractory multiple myeloma before analyzing findings in the context of respective real-world outcomes from the bortezomib/lenalidomide era. Study endpoints included the 52-week PFS rate in second and third line of therapy (LOT), mPFS-2 across the first and second LOT, the ORR, reasons for discontinuation, and the treatment duration per therapeutic algorithm. Data from 107 patients were collected. The median follow-up was 2.0 years. Of the subjects who met the selection criteria for the second LOT, 72.2% maintained the PFS at 52 weeks. In the third-line setting, the PFS rate at 52 weeks was 63.5%. The mPFS across the first and second, the second, and the third LOTs were 26, 17, and 15 months, respectively. The ORR was 76.1% in the second and 69.7% in the third LOT. After non-response or progression, the main reason for drug discontinuation was treatment intolerability. The second-line ORR and the 52-week PFS rate were similar to previous real-world findings from the bortezomib/lenalidomide era. The cumulative mPFS across the second and third LOTs was higher than the respective mPFS across the first and second LOTs. Despite its limitations, the methodology and findings from this study may be used in future clinical and economic evaluations across all hematological malignancies.Newer methodologies are needed to assess the real-world comparative effectiveness of a "generation" of pharmaceutical innovation versus the prior standard of care. This chart review study aimed to first evaluate the cumulative clinical benefits of pharmaceutical innovation in everyday relapse/refractory multiple myeloma before analyzing findings in the context of respective real-world outcomes from the bortezomib/lenalidomide era. Study endpoints included the 52-week PFS rate in second and third line of therapy (LOT), mPFS-2 across the first and second LOT, the ORR, reasons for discontinuation, and the treatment duration per therapeutic algorithm. Data from 107 patients were collected. The median follow-up was 2.0 years. Of the subjects who met the selection criteria for the second LOT, 72.2% maintained the PFS at 52 weeks. In the third-line setting, the PFS rate at 52 weeks was 63.5%. The mPFS across the first and second, the second, and the third LOTs were 26, 17, and 15 months, respectively. The ORR was 76.1% in the second and 69.7% in the third LOT. After non-response or progression, the main reason for drug discontinuation was treatment intolerability. The second-line ORR and the 52-week PFS rate were similar to previous real-world findings from the bortezomib/lenalidomide era. The cumulative mPFS across the second and third LOTs was higher than the respective mPFS across the first and second LOTs. Despite its limitations, the methodology and findings from this study may be used in future clinical and economic evaluations across all hematological malignancies. On rare occasions, a handful of innovative cancer drugs may successfully go through clinical trials and manage to obtain simultaneous regulatory approvals to treat a specific disease, providing hope for improved treatment outcomes. In the past few years, physicians in North America, Europe, and other countries with stronger economies have been able to use several of the recently approved drugs to treat a blood cancer called multiple myeloma, once older therapies have failed. This study looked at the treatment outcomes associated with the wave of newer drugs in patients diagnosed with multiple myeloma in Greece. The results showed that approximately three-quarters of patients who received one of the newer drugs after having progressed on front-line therapies remained in remission a year after initiating treatment. This finding was comparable to the results from previous studies in Greek patients who were diagnosed with relapsed or refractory multiple myeloma and had previously used other therapies. |
| Audience | Academic |
| Author | Misidou, Christina Kontogiorgis, Christos Spanoudakis, Emmanouil Symeonidou, Marianthi Giannakoulas, Nikolaos Intzes, Stergios Nena, Evangelia Terpos, Evangelos Delimpasi, Sosana Constantinidis, Theodoros C. Petrakis, Ioannis Loutsidi, Natasa E. |
| Author_xml | – sequence: 1 givenname: Ioannis orcidid: 0000-0001-7678-5164 surname: Petrakis fullname: Petrakis, Ioannis – sequence: 2 givenname: Christos orcidid: 0000-0001-7835-8246 surname: Kontogiorgis fullname: Kontogiorgis, Christos – sequence: 3 givenname: Evangelia orcidid: 0000-0003-0381-4715 surname: Nena fullname: Nena, Evangelia – sequence: 4 givenname: Sosana surname: Delimpasi fullname: Delimpasi, Sosana – sequence: 5 givenname: Natasa E. surname: Loutsidi fullname: Loutsidi, Natasa E. – sequence: 6 givenname: Emmanouil surname: Spanoudakis fullname: Spanoudakis, Emmanouil – sequence: 7 givenname: Stergios surname: Intzes fullname: Intzes, Stergios – sequence: 8 givenname: Christina orcidid: 0000-0002-7771-7419 surname: Misidou fullname: Misidou, Christina – sequence: 9 givenname: Marianthi surname: Symeonidou fullname: Symeonidou, Marianthi – sequence: 10 givenname: Nikolaos surname: Giannakoulas fullname: Giannakoulas, Nikolaos – sequence: 11 givenname: Theodoros C. orcidid: 0000-0003-3100-0823 surname: Constantinidis fullname: Constantinidis, Theodoros C. – sequence: 12 givenname: Evangelos orcidid: 0000-0001-5133-1422 surname: Terpos fullname: Terpos, Evangelos |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38136391$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkk9v3CAQxa0qVZOmOfdWIfWSHpxgsA0-Vdt00660q0S7qXq0WBgnRBg2gCPtd-6HKPGm_1aFwyD0m5mnp_c6O7DOQpa9LfAZpQ0-l8JK8KGoSFnxsn6RHRHMSF7XTXnw1_swOwnhHqdDacFq9io7pLygNW2Ko-zHZwcBxTtAK90PJgoLbghoZqN3apBRO4tch1bwCF4YdH0nfC8kDFFLYQLSduy9diHmc7DCaOV6rQBNvUA3XthgRAQUHfoEMYJHV0OUroexcwlGbAKk2nkho_NbtEgS9MYAWmzBuF58RJfaKm1vA-q868dlSxAm_-68UUmmdY9iFJnm7Tej0-V0MkezxeIDWsVBbd9kL7ukGk6e63H27XJ6c_E1n199mV1M5rmknMW85kCrUhakTr7yquSywKoQrKadqkmTjFVq3Yh1wytOuGo6giUDRtfAG1Lzjh5np7u5G-8eBgix7XWQYMzO3ZY0uKoIxkWT0Pd76L0bfDJypEpe05IUf6hbYaDVtnMxOfY0tJ0wxsqGMcwSdfYfKl0FvZYpO51O__80vHtePqx7UO3G6174bfsrHgk43wHSuxA8dL-RArdPGWz3Mkh_AgID0LM |
| Cites_doi | 10.1182/blood-2019-124832 10.1080/17474086.2020.1729734 10.3390/jpm12091451 10.1007/s00277-018-3361-2 10.1007/s00277-020-03985-9 10.1016/j.clml.2017.06.013 10.1111/bjh.14213 10.1016/S2352-3026(22)00165-X 10.1182/blood-2022-156225 10.1007/s00277-020-03981-z 10.1159/000520312 10.1016/j.beha.2020.101145 10.3390/curroncol29070355 10.1016/S1470-2045(20)30756-7 10.1038/leu.2017.329 10.1038/s41408-018-0141-0 10.1002/hon.2820 10.1007/s00277-013-1841-y 10.1001/jama.2022.0003 10.1007/s00277-022-05058-5 10.3390/curroncol30020179 10.1016/j.clml.2021.01.018 10.1007/s00277-021-04534-8 10.1016/j.clml.2017.05.003 10.2217/fon-2019-0013 10.1182/blood-2020-134475 10.1016/S1470-2045(16)30206-6 10.1007/s00277-020-04329-3 10.1080/17474086.2019.1668763 10.3389/fonc.2022.844779 10.3906/sag-1611-97 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2023 MDPI AG 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: COPYRIGHT 2023 MDPI AG – notice: 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | AAYXX CITATION NPM 3V. 7T5 7TO 7XB 8FE 8FH 8FK 8G5 ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO GNUQQ GUQSH H94 HCIFZ LK8 M2O M7P MBDVC PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 |
| DOI | 10.3390/cancers15245846 |
| DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Immunology Abstracts Oncogenes and Growth Factors Abstracts ProQuest Central (purchase pre-March 2016) ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni) ProQuest Central ProQuest Central UK/Ireland ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection Biological Sciences Research Library Biological Science Database Research Library (Corporate) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database Research Library Prep ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences Natural Science Collection ProQuest Central Korea Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Central (New) ProQuest Biological Science Collection ProQuest Central Basic ProQuest One Academic Eastern Edition Biological Science Database ProQuest SciTech Collection ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef Publicly Available Content Database PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2072-6694 |
| ExternalDocumentID | A777497707 38136391 10_3390_cancers15245846 |
| Genre | Journal Article |
| GeographicLocations | Greece Eastern Europe |
| GeographicLocations_xml | – name: Eastern Europe – name: Greece |
| GrantInformation_xml | – fundername: Takeda Hellas S.A. grantid: NA |
| GroupedDBID | --- 53G 5VS 8FE 8FH 8G5 AADQD AAFWJ AAYXX ABDBF ABUWG ACUHS ADBBV AFKRA AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ CCPQU CITATION DIK DWQXO E3Z EBD ESX GNUQQ GUQSH GX1 HCIFZ HYE IAO IHR ITC KQ8 LK8 M2O M48 M7P MODMG M~E OK1 P6G PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC RPM TUS 3V. GROUPED_DOAJ NPM PMFND 7T5 7TO 7XB 8FK H94 MBDVC PKEHL PQEST PQGLB PQUKI PRINS Q9U 7X8 PUEGO |
| ID | FETCH-LOGICAL-c387t-68e354c1264588548c10d1a763fd629207ddb9ab985828d9f20c7e73be89268f3 |
| IEDL.DBID | M48 |
| ISSN | 2072-6694 |
| IngestDate | Fri Sep 05 08:52:59 EDT 2025 Fri Jul 25 10:33:47 EDT 2025 Tue Jun 17 22:22:04 EDT 2025 Tue Jun 10 21:27:38 EDT 2025 Thu Jan 02 22:34:43 EST 2025 Tue Jul 01 01:21:38 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 24 |
| Keywords | multiple myeloma real world daratumumab pomalidomide carfilzomib ixazomib |
| Language | English |
| License | https://creativecommons.org/licenses/by/4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c387t-68e354c1264588548c10d1a763fd629207ddb9ab985828d9f20c7e73be89268f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-3100-0823 0000-0001-5133-1422 0000-0002-7771-7419 0000-0001-7678-5164 0000-0001-7835-8246 0000-0003-0381-4715 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/cancers15245846 |
| PMID | 38136391 |
| PQID | 2904863421 |
| PQPubID | 2032421 |
| ParticipantIDs | proquest_miscellaneous_2905520019 proquest_journals_2904863421 gale_infotracmisc_A777497707 gale_infotracacademiconefile_A777497707 pubmed_primary_38136391 crossref_primary_10_3390_cancers15245846 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-12-01 |
| PublicationDateYYYYMMDD | 2023-12-01 |
| PublicationDate_xml | – month: 12 year: 2023 text: 2023-12-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland – name: Basel |
| PublicationTitle | Cancers |
| PublicationTitleAlternate | Cancers (Basel) |
| PublicationYear | 2023 |
| Publisher | MDPI AG |
| Publisher_xml | – name: MDPI AG |
| References | Maura (ref_5) 2020; 33 Richardson (ref_6) 2019; 134 Bertamini (ref_21) 2022; 12 Costello (ref_32) 2019; 15 Katodritou (ref_14) 2018; 97 Stalker (ref_16) 2022; 29 Bhatt (ref_7) 2023; 30 Katodritou (ref_13) 2014; 93 Bringhen (ref_30) 2017; 17 Kumar (ref_15) 2016; 17 Mele (ref_17) 2021; 100 Heider (ref_4) 2021; 44 Cohen (ref_24) 2020; 99 Yong (ref_25) 2016; 175 LeBlanc (ref_22) 2021; 5 Davies (ref_27) 2021; 100 Tanenbaum (ref_10) 2023; 102 Chari (ref_26) 2020; 13 Terpos (ref_20) 2020; 136 Uysal (ref_19) 2018; 48 Moreau (ref_9) 2021; 22 Richardson (ref_29) 2018; 8 Huang (ref_2) 2022; 9 Rocchi (ref_18) 2021; 39 ref_3 Petrakis (ref_11) 2019; 12 Girvan (ref_31) 2022; 140 Chim (ref_8) 2018; 32 Terpos (ref_23) 2020; 99 Cowan (ref_1) 2022; 327 Gavriatopoulou (ref_12) 2021; 21 Shah (ref_28) 2017; 17 |
| References_xml | – volume: 134 start-page: 3487 year: 2019 ident: ref_6 article-title: The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone publication-title: Blood doi: 10.1182/blood-2019-124832 – volume: 13 start-page: 421 year: 2020 ident: ref_26 article-title: Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): A comparison of VRd, KRd, and Ird publication-title: Expert Rev. Hematol. doi: 10.1080/17474086.2020.1729734 – ident: ref_3 doi: 10.3390/jpm12091451 – volume: 97 start-page: 1671 year: 2018 ident: ref_14 article-title: Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: Treatment at biochemical relapse is a significant prognostic factor for progression-free survival publication-title: Ann. Hematol. doi: 10.1007/s00277-018-3361-2 – volume: 99 start-page: 1273 year: 2020 ident: ref_24 article-title: Ixazomib-Based Regimens for Relapsed/Refractory Multiple Myeloma: Are Real-World Data Compatible with Clinical Trial Outcomes? A Multi-Site Israeli Registry Study publication-title: Ann. Hematol. doi: 10.1007/s00277-020-03985-9 – volume: 17 start-page: 575 year: 2017 ident: ref_28 article-title: Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes publication-title: Clin. Lymphoma Myeloma Leuk. doi: 10.1016/j.clml.2017.06.013 – volume: 175 start-page: 252 year: 2016 ident: ref_25 article-title: Multiple Myeloma: Patient outcomes in real world practice publication-title: Br. J. Haematol. doi: 10.1111/bjh.14213 – volume: 9 start-page: e670 year: 2022 ident: ref_2 article-title: The epidemiological landscape of multiple myeloma: A global cancer registry estimate of disease burden, risk factors, and temporal trends publication-title: Lancet Haematol. doi: 10.1016/S2352-3026(22)00165-X – volume: 140 start-page: 5288 year: 2022 ident: ref_31 article-title: Treatment patterns and outcomes in patients with relapsed/refractory multiple myeloma receiving >3 lines of Therapy: A real world evaluation in the United States publication-title: Blood doi: 10.1182/blood-2022-156225 – volume: 99 start-page: 1049 year: 2020 ident: ref_23 article-title: Real-World Effectiveness and Safety of Ixazomib-Lenalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma publication-title: Ann. Hematol. doi: 10.1007/s00277-020-03981-z – volume: 44 start-page: 672 year: 2021 ident: ref_4 article-title: Multiple Myeloma: Molecular Pathogenesis and Disease Evolution publication-title: Oncol. Res. Treat. doi: 10.1159/000520312 – volume: 33 start-page: 101145 year: 2020 ident: ref_5 article-title: Reconstructing the evolutionary history of multiple myeloma publication-title: Best Pract. Res. Clin. Haematol. doi: 10.1016/j.beha.2020.101145 – volume: 29 start-page: 4464 year: 2022 ident: ref_16 article-title: Clinical Management of Triple-Class Refractory Multiple Myeloma: A Review of Current Strategies and Emerging Therapies publication-title: Curr. Oncol. doi: 10.3390/curroncol29070355 – volume: 22 start-page: E105 year: 2021 ident: ref_9 article-title: Treatment of relapsed and refractory multiple myeloma: Recommendations from the International Myeloma Working Group publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(20)30756-7 – volume: 32 start-page: 252 year: 2018 ident: ref_8 article-title: Management of relapsed and refractory multiple myeloma: Novel agents, antibodies, immunotherapies and beyond publication-title: Leukemia doi: 10.1038/leu.2017.329 – volume: 8 start-page: 109 year: 2018 ident: ref_29 article-title: Interpreting clinical trial data in multiple myeloma: Translating findings to the real-world setting publication-title: Blood Cancer J. doi: 10.1038/s41408-018-0141-0 – volume: 39 start-page: 41 year: 2021 ident: ref_18 article-title: A Real-World Efficacy and Safety Analysis of Combined Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Relapsed/Refractory Multiple Myeloma publication-title: Hematol. Oncol. doi: 10.1002/hon.2820 – volume: 93 start-page: 129 year: 2014 ident: ref_13 article-title: “Real-world” data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: A study of the Greek Myeloma Study Group publication-title: Ann. Hematol. doi: 10.1007/s00277-013-1841-y – volume: 327 start-page: 464 year: 2022 ident: ref_1 article-title: Diagnosis and Management of Multiple Myeloma: A Review publication-title: JAMA doi: 10.1001/jama.2022.0003 – volume: 102 start-page: 1 year: 2023 ident: ref_10 article-title: The emerging therapeutic landscape of relapsed/refractory multiple myeloma publication-title: Ann. Hematol. doi: 10.1007/s00277-022-05058-5 – volume: 30 start-page: 2322 year: 2023 ident: ref_7 article-title: Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse publication-title: Curr. Oncol. doi: 10.3390/curroncol30020179 – volume: 21 start-page: 379 year: 2021 ident: ref_12 article-title: Real-World Treatment of Patients with Relapsed/Refractory Myeloma publication-title: Clin. Lymphoma Myeloma Leuk. doi: 10.1016/j.clml.2021.01.018 – volume: 100 start-page: 2325 year: 2021 ident: ref_27 article-title: Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US publication-title: Ann. Hematol. doi: 10.1007/s00277-021-04534-8 – volume: 17 start-page: 391 year: 2017 ident: ref_30 article-title: New Agents in Multiple Myeloma: An Examination of Safety Profiles publication-title: Clin. Lymphoma Myeloma Leuk. doi: 10.1016/j.clml.2017.05.003 – volume: 15 start-page: 1411 year: 2019 ident: ref_32 article-title: INSIGHT MM: A large, global, prospective, non-interventional, real-world study of patients with multiple myeloma publication-title: Future Oncol. doi: 10.2217/fon-2019-0013 – volume: 136 start-page: 38 year: 2020 ident: ref_20 article-title: Real-World Evidence of the Use of Carfilzomib Among Multiple Myeloma Patients With at Least One Prior Therapy Across 10 European Countries and Israel publication-title: Blood doi: 10.1182/blood-2020-134475 – volume: 5 start-page: 777 year: 2021 ident: ref_22 article-title: Outcomes of Daratumumab-Containing Regimens in the Treatment of Relapsed Multiple Myeloma: Real-World Data from the Canadian Myeloma Research Group Database publication-title: Hemasphere – volume: 17 start-page: e328 year: 2016 ident: ref_15 article-title: International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(16)30206-6 – volume: 100 start-page: 429 year: 2021 ident: ref_17 article-title: Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: The Real-Life Experience of Rete Ematologica Pugliese (REP) publication-title: Ann. Hematol. doi: 10.1007/s00277-020-04329-3 – volume: 12 start-page: 1063 year: 2019 ident: ref_11 article-title: Unraveling innovation potential in the real-world setting: Eighteen novel agents with twenty-six approved European indications, in the management of leukemias, lymphomas, and multiple myeloma publication-title: Expert Rev. Hematol. doi: 10.1080/17474086.2019.1668763 – volume: 12 start-page: 844779 year: 2022 ident: ref_21 article-title: Beyond clinical trials in patients with multiple myeloma: A critical review of real-world results publication-title: Front. Oncol. doi: 10.3389/fonc.2022.844779 – volume: 48 start-page: 80 year: 2018 ident: ref_19 article-title: Carfilzomib experience in relapsed/refractory multiple myeloma: A single-center experience publication-title: Turk. J. Med. Sci. doi: 10.3906/sag-1611-97 |
| SSID | ssj0000331767 |
| Score | 2.3187602 |
| Snippet | Newer methodologies are needed to assess the real-world comparative effectiveness of a “generation” of pharmaceutical innovation versus the prior standard of... Newer methodologies are needed to assess the real-world comparative effectiveness of a "generation" of pharmaceutical innovation versus the prior standard of... On rare occasions, a handful of innovative cancer drugs may successfully go through clinical trials and manage to obtain simultaneous regulatory approvals to... Simple SummaryOn rare occasions, a handful of innovative cancer drugs may successfully go through clinical trials and manage to obtain simultaneous regulatory... |
| SourceID | proquest gale pubmed crossref |
| SourceType | Aggregation Database Index Database |
| StartPage | 5846 |
| SubjectTerms | Analysis Antimitotic agents Antineoplastic agents Bortezomib Care and treatment Clinical outcomes Clinical trials Drug approval Enrollments Health care policy Immunotherapy Innovations Malignancy Medical innovations Medical research Medicine, Experimental Missing data Multiple myeloma Oncology Patient outcomes Patients Pharmaceuticals Pharmacoeconomics Remission Statistical analysis Targeted cancer therapy |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fb9MwELZGJyFeEL8JDHRISIyHaE3S2M4DmjpotaGlTB2T9hY5tiMqbUlpMqT-z_wR3DlJoX3gKQ-JY8t3vvts393H2HuFsFhwYi9TSUxFtTXaQa59KzkPdWiUtZTgnM746dXo63V8vcdmfS4MhVX2NtEZalNpOiM_ChMqDheNwuB4-dMn1ii6Xe0pNFRHrWA-uRJj99h-SKzKA7Z_MpldzDenLsMI_SUXbY2fCPf7R5omd1WjG6MbQ77lnnaN9A70dC5o-og97LAjjFthP2Z7tnzC7qfd7fhT9vtLZWtARAeXCwoUVKXFfT2cUTC6aavEQlXApf1FB1Fw8ePf4-waFqVrS_S9_rklgG6q24WxMFkpcD7tBoEpNBWcuBwg-HbX4NxZ15KC6pa1xWexchQ-a0i7WEVI1_amulXHMF24HJoaKKnFdTZHnOq7gB4cZs_PSv_bbQyH88n4HM7S9CNQ7OP6GbuaTr5_PvU7NgdfR1I0Ppc2QlUIEIHFUuJGSQdDEyi0b4XhxJkljMkTlSeSbvJMUoRDLayIciuTkMsies4GZVXalwwCKUSBZtzEWoxyqZPc5pQTH6HMRR5wjx32QsyWbdGODDc7JO9sR94e-0BCzmg5Nzg_qstKwI6oMFY2FoiPESMPhccOtr7EZai3X_dqknVmoM7-Kq3H3m1eU0sKbXNKQN_EVPsqSDz2olWvzaARTkUIIYNX___5a_YgROzVRtkcsEGzurNvECs1-dtuAfwB0NMWmg priority: 102 providerName: ProQuest |
| Title | Does the Simultaneous Introduction of Several Pharmaceuticals in the Post-Lenalidomide Era Translate to Better Outcomes in Relapse Refractory Multiple Myeloma? Findings from the Real-World Innovation in Multiple Myeloma (REAL IMM) Study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38136391 https://www.proquest.com/docview/2904863421 https://www.proquest.com/docview/2905520019 |
| Volume | 15 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 2072-6694 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000331767 issn: 2072-6694 databaseCode: KQ8 dateStart: 20090101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVEBS databaseName: EBSCOhost Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 2072-6694 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000331767 issn: 2072-6694 databaseCode: ABDBF dateStart: 20100901 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 2072-6694 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000331767 issn: 2072-6694 databaseCode: DIK dateStart: 20090101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 2072-6694 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000331767 issn: 2072-6694 databaseCode: GX1 dateStart: 20090101 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2072-6694 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000331767 issn: 2072-6694 databaseCode: M~E dateStart: 20090101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 2072-6694 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000331767 issn: 2072-6694 databaseCode: RPM dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 2072-6694 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000331767 issn: 2072-6694 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 2072-6694 dateEnd: 20250930 omitProxy: true ssIdentifier: ssj0000331767 issn: 2072-6694 databaseCode: M48 dateStart: 20091201 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3fb9MwELbYJiFeEOPXAqM6JCR4CTROYzsPaNpGy0BkTBuV-hYltiMqdclIMkT_XP4T7px00GoPPOUhcWL5znffxXf3MfYqQ1gsBbGXZXFETbU12kGhfauE4JqbzFoqcE5Oxcl09HkWzf7SAfUL2Nwa2hGf1LRevP31Y3mAG_49RZwYsr_TtD51g56IDv3EFttBt8RJxZMe6zuzHKKrdIyyfCi5L0Q86lr93PaONS-1aas3EKjzRJMH7H4PIeGwk_kuu2PLh-xu0h-SP2K_P1S2AQR2cDGnfMGstBjewyfKSTdds1ioCriwP-l_FJx9__evdgPz0o0lFl__iyWcbqrLubEwrjNwrm2B-BTaCo5cKRB8vW5Rba0bSbl1V43Fa1E7Jp8lJH3KIiRLu6guswOYzF0pTQNU2-I-do5w1Xd5PTjNFU0rvW9zMFDe4_Ixm07G345P_J7Jwdehkq0vlA1RDQJEX5FSGCTpYGiCDG1bYQTxZUlj8jjLY0WneCYu-FBLK8PcqpgLVYRP2HZZlXaPQaCkLNCEm0jLUa50nNuc6uFDBCoyD4TH3qwkl151DTtSDHRIyOmGkD32miSbknK1uChZX5GAH6KmWOmhRGyM-HgoPba_9iRuQb1-e6Ub6UqDUx5TN8NwxAOPvby5TSMprc1Jnp6JqO9VEHvsaadTN5NGKBUifAye_fcsn7N7HCFYl2yzz7bb-tq-QMjU5gO2czQ-PTsfsK2Ps2DgNsYfWSkZ6A |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELfGJgEviP8UBhwSiPEQrYlbO3mYpo61allTpm6T9pYltiMqbU1pUlC_HJ-ID8GdkxTaB972lAfHjpXz3f1s392PsfcxwmIpiL0sDtpUVFuhHRTKMb4QnvJ0bAwlOIcj0b9ofblsX26xX3UuDIVV1jbRGmqdKToj3_cCKg7HW557OPvuEGsU3a7WFBpxRa2gD2yJsSqx48Qsf-IWLj8YHKO8P3her3v-ue9ULAOO4r4sHOEbjlN0ERm0fR8BvHKb2o1R71ItiMtJap0EcRL4dMOkg9RrKmkkT4wfeMJPOY57h-0g7OCoVTtH3dHpeHXK0-Ton4UsawpxHjT3FQlznqPbpBtKseYON53CBtS1Lq_3kD2osCp0ysX1iG2Z6WN2N6xu45-w38eZyQERJJxNKDAxnppskcOAgt91WZUWshTOzA86-ILTb_8en-cwmdq-RBfsDA1tCHR2M9EGuvMYrA-9RiAMRQZHNucIvi4KlJWxPSmIb5YbfKZzSxm0hLCKjYRwaa6zm_gQehObs5MDJdHYj40RFzs2gAinWfPB0nibnWFv3O0MYRCGn4BiLZdP2cWtyPUZ255mU_OCgetLmaLb0G0lW4mvgsQklIPPERzJxBUNtlcLMZqVRUIi3FyRvKMNeTfYRxJyROajwP8TV1kQ-CEqxBV1JOJxxORN2WC7a2-i2qv15nqZRJXZyaO_StJg71bN1JNC6ewioHfaVGvLDRrsebm8VpNG-MYRsrov_z_4W3avfx4Oo-FgdPKK3fcQ95URPrtsu5gvzGvEaUXyplIGYFe3rX9_ANRrUcU |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtNAEF6VVKq4IP4JFBgkEOVgxT_Jrn2oqpQkamgcopRKvRl7dy0itXGIHVBekWfhIZhZ24HkwK0nH9a7Xnl2Zr7d_WaGsbcxwmLBqXpZHHQoqbZEO8ilpX3OXemqWGsKcA7H_Oyy_emqc7XHftWxMESrrG2iMdQqk3RG3nIDSg7ntV2nlVa0iElvcLL4blEFKbpprctpxFWZBXVs0o1VQR7nev0Tt3P58bCHsn_nuoP-l49nVlVxwJKeLwqL-9rD6TqIEjq-j2BeOrZyYtTBVHGq6ySUSoI4CXy6bVJB6tpSaOEl2g9c7qcejnuH7QuKF22w_dP-eDLdnPjYHvpqLsr8Qp4X2C1Jgl3m6ELptpJvucZdB7EDe437G9xn9yrcCt1yoT1ge3r-kB2E1c38I_a7l-kcEE3CxYxIivFcZ6schkSEV2WGWshSuNA_6BAMJt_-PUrPYTY3fal0sDXStDlQ2c1MaegvYzD-9BpBMRQZnJr4I_i8KlBu2vQkQt8i1_hMl6Z80BrCiicJ4VpfZzfxCQxmJn4nBwqoMR-bIka2DJkIp1nXhqXxdjvD0bTfHcEwDD8A8S7Xj9nlrcj1CWvMs7l-xsDxhUjRhaiOFO3El0GiE4rH9xAoicThTXZUCzFalAlDItxokbyjHXk32XsSckSmpMD_E1cREfghSsoVdQVic8Tntmiyw6030QTI7eZ6mUSVCcqjvwrTZG82zdSTaHVmEdA7Hcq75QRN9rRcXptJI5TzEL46z_8_-Gt2gHoYjYbj8xfsrosQsCT7HLJGsVzplwjZiuRVpQvAvt62-v0BhfBV_w |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Does+the+Simultaneous+Introduction+of+Several+Pharmaceuticals+in+the+Post-Lenalidomide+Era+Translate+to+Better+Outcomes+in+Relapse+Refractory+Multiple+Myeloma%3F+Findings+from+the+Real-World+Innovation+in+Multiple+Myeloma+Study&rft.jtitle=Cancers&rft.au=Petrakis%2C+Ioannis&rft.au=Kontogiorgis%2C+Christos&rft.au=Nena%2C+Evangelia&rft.au=Delimpasi%2C+Sosana&rft.date=2023-12-01&rft.pub=MDPI+AG&rft.issn=2072-6694&rft.eissn=2072-6694&rft.volume=15&rft.issue=24&rft_id=info:doi/10.3390%2Fcancers15245846&rft.externalDocID=A777497707 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2072-6694&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2072-6694&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2072-6694&client=summon |